| Tissue factor pathway inhibitor and antithrombin trial results. | |
| | |
MedLine Citation:
|
PMID: 15992666 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The endogenous plasma anticoagulant proteins tissue factor pathway inhibitor (TFPI) and antithrombin (AT) have both been extensively studied in large, multinational phase III clinical trials in patients with severe sepsis. The TFPI and AT trials failed to result in significant reductions in the 28-day, all-cause mortality rates in their respective study populations. However, there appear to be definable patient populations within each study that may have benefited from TFPI or AT. Drug-drug interactions and dosing issues were observed in both trials. The similarities and differences of each anticoagulant and the lessons learned from the recent phase III clinical trials are examined in this review. |
| | |
Authors:
|
Steven P LaRosa; Steven M Opal |
Related Documents
:
|
17050456 - The debate: a case for randomized controls in invasive aspergillosis. 20730696 - The utility of cardiovascular drugs in the treatment of cerebrovascular disease. 18275926 - Vascular cognitive impairment: current concepts and clinical developments. 16906456 - Application of clinical trial simulation to compare proof-of-concept study designs for ... 18771856 - In vitro evaluation of the growth inhibitory activities of 15 drugs against babesia gib... 11956676 - Knowledge on drug dosages of ward physicians. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Critical care clinics Volume: 21 ISSN: 0749-0704 ISO Abbreviation: Crit Care Clin Publication Date: 2005 Jul |
Date Detail:
|
Created Date: 2005-07-04 Completed Date: 2005-08-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8507720 Medline TA: Crit Care Clin Country: United States |
Other Details:
|
Languages: eng Pagination: 433-48 Citation Subset: IM |
Affiliation:
|
Infectious Disease Division, Rhode Island Hospital, Gerry House 113, 593 Eddy Street, Providence, RI 02903, USA. slarosa@lifespan.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anticoagulants / therapeutic use* Double-Blind Method Fibrinolytic Agents / therapeutic use* Heparin / therapeutic use* Humans Lipoproteins / therapeutic use* Multicenter Studies as Topic Randomized Controlled Trials as Topic Sepsis / drug therapy*, mortality Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Lipoproteins; 0/lipoprotein-associated coagulation inhibitor; 9005-49-6/Heparin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sepsis and coagulation.
Next Document: Disseminated intravascular coagulation: What's new?